Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Antiretroviral Drugs. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Novel synthetic method for Abacavir intermediate ensures high purity and streamlined manufacturing for global pharmaceutical supply chains reducing solvent use and operational complexity significantly.
Patent CN110358804B reveals high-purity enzymatic resolution for dolutegravir synthesis, offering scalable biocatalysis solutions for reliable pharmaceutical intermediate suppliers.
Novel synthesis route for Rilpivirine intermediate offering high purity and scalable production for global pharmaceutical supply chains.
Advanced synthesis of Saquinavir intermediate via L-Phenylalanine. High yield (75%), >99% optical purity. Cost-effective route for API manufacturing.
Patent CN115594600A reveals a safer, one-step synthesis of chiral (R)-3-aminobutanol using borohydride, offering significant cost reduction and supply chain reliability for API manufacturers.
High-purity synthesis route for Abacavir intermediate via phosphorus-free chemistry ensuring supply chain stability and cost efficiency for global pharmaceutical manufacturers.
Patent CN101003511B details a novel synthesis route for Abacavir intermediates offering simplified operations and enhanced supply chain reliability for global pharmaceutical manufacturing.
Explore patent CN102617487A for novel pyrimidinone compounds. Discover cost-effective synthesis routes and reliable supply chain solutions for HIV-1 integrase inhibitors.
Patent CN113512569B details a green enzymatic route for Lopinavir intermediates. Achieve high purity and cost reduction in API manufacturing with our advanced biocatalytic solutions.
Patent CN109942514A reveals efficient Ir-catalyzed route for Atazanavir intermediate. Enables cost reduction in API manufacturing and reliable supply chain continuity.
Patent CN110862325B reveals a novel asymmetric cycloaddition route for high-purity Bictegravir intermediates, offering significant cost reduction and supply chain reliability.
Solve emtricitabine purification challenges with 87% yield and 99.9% HPLC purity. Reduce impurities and scale efficiently for HIV drug production.